Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

نویسندگان

  • Jeffrey N. Miner
  • Philip K. Tan
  • David Hyndman
  • Sha Liu
  • Cory Iverson
  • Payal Nanavati
  • David T. Hagerty
  • Kimberly Manhard
  • Zancong Shen
  • Jean-Luc Girardet
  • Li-Tain Yeh
  • Robert Terkeltaub
  • Barry Quart
چکیده

BACKGROUND Excess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most patients with gout, and the renal urate transporter (URAT)1 is important for regulation of serum uric acid (sUA) levels. The URAT1 inhibitors probenecid and benzbromarone are used as gout therapies; however, their use is limited by drug-drug interactions and off-target toxicity, respectively. Here, we define the mechanism of action of lesinurad (Zurampic®; RDEA594), a novel URAT1 inhibitor, recently approved in the USA and Europe for treatment of chronic gout. METHODS sUA levels, fractional excretion of uric acid (FEUA), lesinurad plasma levels, and urinary excretion of lesinurad were measured in healthy volunteers treated with lesinurad. In addition, lesinurad, probenecid, and benzbromarone were compared in vitro for effects on urate transporters and the organic anion transporters (OAT)1 and OAT3, changes in mitochondrial membrane potential, and human peroxisome proliferator-activated receptor gamma (PPARγ) activity. RESULTS After 6 hours, a single 200-mg dose of lesinurad elevated FEUA 3.6-fold (p < 0.001) and reduced sUA levels by 33 % (p < 0.001). At concentrations achieved in the clinic, lesinurad inhibited activity of URAT1 and OAT4 in vitro, did not inhibit GLUT9, and had no effect on ABCG2. Lesinurad also showed a low risk for mitochondrial toxicity and PPARγ induction compared to benzbromarone. Unlike probenecid, lesinurad did not inhibit OAT1 or OAT3 in the clinical setting. CONCLUSION The pharmacodynamic effects and in vitro activity of lesinurad are consistent with inhibition of URAT1 and OAT4, major apical transporters for uric acid. Lesinurad also has a favorable selectivity and safety profile, consistent with an important role in sUA-lowering therapy for patients with gout.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Lesinurad combination therapy with allopurinol in gout: do CLEAR studies make the treatment of gout clearer?

Gout is an often forgotten disease, despite being the most common inflammatory arthritis in adults in the Western world. Lesinurad, a new urate-lowering therapy (ULT), is now approved for the treatment of gout in the USA and the European Union, 6 and is in phase III programmes as a combination therapy in many other countries. Lesinurad is a selective inhibitor of urate/anion exchanger 1 and org...

متن کامل

Lesinurad: what the nephrologist should know

Lesinurad is an oral inhibitor of the monocarboxylic/urate transporter URAT1 encoded by the SLC22A12 gene. Market authorization was granted in February 2016 in Europe and December 2015 in the USA. As a potentially nephrotoxic uricosuric drug acting on the kidney, nephrologists should become familiar with its indications and safety profile. The approved indication is treatment of gout in combina...

متن کامل

Lesinurad: A significant advancement or just another addition to existing therapies of gout?

Gout is a metabolic disorder that usually presents as recurrent episodes of acute arthritis due to deposition of crystals in joints and cartilages. Despite the availability of several drugs for gout, its management is still less than adequate. There is always a search for newer, safer, and more potent urate-lowering therapies for treating patients inadequately controlled with available drugs. L...

متن کامل

NEW DRUG APPROVALS Zurampic for Hyperuricemia Associated With Gout

NEW DRUG APPROVALS Zurampic for Hyperuricemia Associated With Gout The FDA has approved lesinurad (Zurampic, AstraZeneca) to treat high levels of uric acid in the blood (hyper­ uricemia) associated with gout. Lesinurad is to be used in combination with a xanthine oxidase inhibitor (XOI), a type of drug approved to reduce the pro­ duction of uric acid in the body. Lesinu­ rad helps the kidney ex...

متن کامل

Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers

INTRODUCTION Lesinurad is a selective uric acid reabsorption inhibitor approved for the treatment of gout in combination with a xanthine oxidase inhibitor (XOI) in patients who have not achieved target serum uric acid (sUA) levels with an XOI alone. Most people with gout have chronic kidney disease. The pharmacokinetics, pharmacodynamics, and safety of lesinurad were assessed in subjects with i...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 18  شماره 

صفحات  -

تاریخ انتشار 2016